Sangamo Therapeutics, Inc. (NASDAQ:SGMO – Get Free Report) shares crossed above its 200-day transferring common throughout buying and selling on Friday . The inventory has a 200-day transferring common of $0.66 and traded as excessive as $0.77. Sangamo Therapeutics shares final traded at $0.72, with a quantity of three,481,646 shares buying and selling arms.
Analyst Upgrades and Downgrades
SGMO has been the topic of various latest analyst stories. StockNews.com started protection on Sangamo Therapeutics in a report on Sunday, July twenty eighth. They issued a “promote” score for the corporate. HC Wainwright reissued a “purchase” score and set a $5.00 value goal on shares of Sangamo Therapeutics in a report on Thursday, August twenty second. One equities analysis analyst has rated the inventory with a promote score, three have issued a maintain score and one has given a purchase score to the corporate. In keeping with information from MarketBeat, Sangamo Therapeutics has a median score of “Maintain” and a consensus value goal of $2.67.
View Our Newest Inventory Report on Sangamo Therapeutics
Sangamo Therapeutics Inventory Down 3.8 %
The enterprise has a 50-day easy transferring common of $0.68 and a two-hundred day easy transferring common of $0.66. The inventory has a market capitalization of $150.03 million, a price-to-earnings ratio of -0.39 and a beta of 1.23.
Sangamo Therapeutics (NASDAQ:SGMO – Get Free Report) final introduced its quarterly earnings information on Tuesday, August sixth. The biopharmaceutical firm reported ($0.17) earnings per share for the quarter, lacking the consensus estimate of ($0.16) by ($0.01). The agency had income of $0.36 million through the quarter, in comparison with analyst estimates of $11.40 million. Sangamo Therapeutics had a adverse internet margin of two,033.69% and a adverse return on fairness of 273.25%. On common, analysts forecast that Sangamo Therapeutics, Inc. will put up -0.47 EPS for the present 12 months.
Hedge Funds Weigh In On Sangamo Therapeutics
Massive buyers have just lately made adjustments to their positions within the enterprise. State Board of Administration of Florida Retirement System boosted its holdings in Sangamo Therapeutics by 61.1% through the first quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical firm’s inventory price $42,000 after shopping for a further 23,650 shares within the final quarter. Cubist Systematic Methods LLC acquired a brand new stake in shares of Sangamo Therapeutics through the 2nd quarter valued at $67,000. Point72 Asia Singapore Pte. Ltd. purchased a brand new stake in shares of Sangamo Therapeutics through the 2nd quarter price $89,000. Marshall Wace LLP grew its holdings in shares of Sangamo Therapeutics by 56.3% within the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical firm’s inventory price $207,000 after buying a further 207,476 shares over the past quarter. Lastly, Mirae Asset International Investments Co. Ltd. acquired a brand new stake in shares of Sangamo Therapeutics through the first quarter price $331,000. Institutional buyers personal 56.93% of the corporate’s inventory.
Sangamo Therapeutics Firm Profile
Sangamo Therapeutics, Inc, a clinical-stage genomic drugs firm, focuses on translating science into medicines that rework the lives of sufferers and households with critical illnesses in america. The corporate’s clinical-stage product candidates are ST-920, a gene remedy product candidate, which is in Section 1/2 scientific research for the remedy of Fabry illness; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) remedy product candidate that’s in Section 1/2 scientific research for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene remedy product candidate, which is in Section 3 scientific trial for the remedy of reasonably extreme to extreme hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell remedy product candidate that’s in Section 1/2 PRECIZN-1 scientific research for the remedy of sickle cell illness.
Featured Articles
Obtain Information & Rankings for Sangamo Therapeutics Every day – Enter your electronic mail handle under to obtain a concise day by day abstract of the most recent information and analysts’ scores for Sangamo Therapeutics and associated firms with MarketBeat.com’s FREE day by day electronic mail publication.
